Becton Dickinson to Invest $3 Billion in U.S. Medical Manufacturing

Becton Dickinson and Co. (NYSE: BDX) has agreed to invest $3 billion to expand medical-product manufacturing in the United States, President Donald Trump announced Tuesday, as his administration seeks to strengthen domestic healthcare supply chains.

Trump said more than $1 billion of the planned investment will be directed toward Nebraska, where Becton Dickinson, commonly known as BD, intends to increase production of essential medical supplies. The expansion will include syringes, needles and other healthcare products, with some needles manufactured using U.S.-produced steel.

BD had not immediately issued a statement regarding Trump's announcement or responded to requests for comment.

The president linked the $3 billion commitment to his administration's proposed tariffs on imported medical devices. Trump said those tariffs are expected to take effect by the end of the year as part of a broader effort to encourage manufacturers to shift production to the United States.

The White House separately announced that BD will invest $110 million to expand production of prefillable syringes at its facility in Columbus, Nebraska. The project is expected to create approximately 120 jobs and comes on top of an earlier $35 million investment at the same manufacturing site.

The latest commitment underscores the Trump administration's push to reduce U.S. dependence on foreign-made medical products considered critical to the country's healthcare system. Increasing domestic production of syringes, needles and other supplies could help strengthen supply-chain resilience while supporting American manufacturing jobs.

Becton Dickinson is one of the world's largest medical technology companies, producing a broad range of devices and healthcare products used by hospitals, laboratories and other medical providers.

The company has also been reshaping its business portfolio this year. In February, BD completed the separation of its Biosciences and Diagnostic Solutions operations into Waters, allowing the medical technology company to focus more closely on its remaining businesses and manufacturing priorities.

The new $3 billion U.S. investment represents a significant expansion of that strategy as Washington increases pressure on healthcare manufacturers to bring more production onshore.